Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 11.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,944 shares of the company’s stock after acquiring an additional 4,799 shares during the quarter. SG Americas Securities LLC’s holdings in Adaptive Biotechnologies were worth $275,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $59,000. B. Riley Wealth Advisors Inc. lifted its position in Adaptive Biotechnologies by 48.1% during the third quarter. B. Riley Wealth Advisors Inc. now owns 20,000 shares of the company’s stock worth $102,000 after buying an additional 6,500 shares in the last quarter. Barclays PLC boosted its stake in Adaptive Biotechnologies by 149.5% during the third quarter. Barclays PLC now owns 230,177 shares of the company’s stock worth $1,180,000 after buying an additional 137,936 shares during the last quarter. Pier Capital LLC grew its holdings in Adaptive Biotechnologies by 20.9% in the 3rd quarter. Pier Capital LLC now owns 1,275,885 shares of the company’s stock valued at $6,533,000 after buying an additional 220,586 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Adaptive Biotechnologies by 2.0% in the 3rd quarter. State Street Corp now owns 2,551,785 shares of the company’s stock worth $13,065,000 after acquiring an additional 48,885 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Wall Street Analysts Forecast Growth

ADPT has been the topic of several recent research reports. The Goldman Sachs Group boosted their price target on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler raised their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Monday, November 11th.

Adaptive Biotechnologies Trading Up 9.2 %

NASDAQ ADPT opened at $8.05 on Thursday. The stock has a market cap of $1.19 billion, a PE ratio of -6.01 and a beta of 1.49. Adaptive Biotechnologies Co. has a twelve month low of $2.28 and a twelve month high of $8.33. The stock has a fifty day simple moving average of $6.76 and a 200-day simple moving average of $5.47.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.